ClinicalTrials.govclosed
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NS
ClinicalTrials.gov study NCT03625323. IPD Sharing: NO. Countries: 1. Publications: 1.
ShareScore
36/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 12
- Access
- 4
- Reuse readiness
- 0
- Engagement
- 8